Skip to main content
TV

ToMore Vision

ToMore Vision utilizes AI-driven multi-modal data analysis to deliver precise, personalized cancer prognoses, enhancing diagnostic accuracy for oncology teams. This technology addresses the challenge of traditional prognosis methods by providing real-time tumor modeling and smart genetics correlation mapping, ultimately improving patient outcomes.

Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Product

Problem

Traditional cancer prognosis methods often lack the precision needed for personalized treatment plans, hindering optimal patient outcomes. Existing approaches struggle to integrate diverse data types and provide real-time insights into tumor behavior and genetic correlations.

Solution

ToMore Vision offers an AI-powered platform that analyzes multi-modal data to deliver precise, personalized cancer prognoses. The platform leverages real-time tumor modeling and smart genetics correlation mapping to enhance diagnostic accuracy for oncology teams. By integrating comprehensive genomics data with advanced AI, ToMore Vision enables healthcare professionals to transcend traditional prognosis methods, offering enhanced accuracy and efficiency in cancer treatment planning. The platform aims to revolutionize prognosis and treatment planning across various health conditions, with a significant focus on oncology, paving the way for a new era in personalized medicine.

Target Audience

The primary users are oncology teams and healthcare professionals seeking to improve cancer treatment planning and patient outcomes through more precise and personalized prognoses.

Features

  • Real-time tumor modeling using AI-driven precision.
  • Multi-modal data analysis integrating diverse data types.
  • Smart genetics correlation mapping for enhanced insights.
  • Accelerated prognosis capabilities for timely decision-making.
This profile is AI-generated and may contain inaccuracies.